normal cellular metabolic activities but can also play an etiopathogenetic role in a variety of conditions, including cardiovascular diseases, neurodegenerative diseases, and cancer.
Although the role of oxidative stress in human physiology and pathology has been intensely studied for several decades, it is still far from being understood. Certainly, the roles of free radicals and antioxidants have been significantly redefined. Some "negative" actions of free radicals in human biology and pathology are now known to be "positive," and the hypothesis that "classical antioxidants" (radical scavengers) could be always beneficial for the human health was not confirmed by several epidemiological and clinical studies. The possible reasons of the failures of the current antioxidant therapies, including methodological pitfalls in the drug development and delivery and the lack of good biological markers to select the patients, have been reviewed elsewhere [1, 2] .
We currently believe that instead of "antioxidants," it is more appropriate to develop "modulators of oxidative stress" because, depending on the condition, it could be more beneficial to reduce or increase the oxidative stress.
In this special issue, several aspects of the modulation of oxidative stress were examined including the role of polyphe- In particular, this special issue contains two interesting contributions coming from INSERM Toulouse. The first one is an original research paper prepared in collaboration with CNRS and Palau Sabatier University in which C. Camare et al. investigated whether 4-hydroxynonenal (4-HNE), an aldehydic lipid oxidation product abundantly present in oxidized LDL, contributes to its proangiogenic properties. Using the immunofluorescence analysis of human atherosclerotic lesions, they found colocalization of HNE adducts with CD31 (marker of the endothelium), indicating a close relationship between 4-HNE and neovascularization. Moreover, they revealed that physiological concentrations of 4-HNE also enhance the formation of tubes by human microvascular endothelial cells (HMEC-1), through mechanisms involving reactive oxygen species (ROS) and activation of the neutral type 2 sphingomyelinase and sphingosine kinase-1 (nSMase2/SK-1) pathway. Eventually, they found that carbonyl scavengers hydralazine and bisvanillyl-hydralazone inhibited such proangiogenic effects of 4-HNE. In their second paper (in this time, a review paper) prepared jointly with partners from Mexico and from INRA in Toulouse, they described in detail features of the wellknown plants of Opuntia spp. and their possible beneficial effects on chronic diseases. Thus, M. del Socorro Santos Díaz et al. point to the differences in the phytochemical composition between wild and domesticated (O. ficus-indica) Opuntia spp., stressing that all Opuntia components (pear, roots, cladodes, seeds, and juice) used as nutritional and pharmaceutical agents exhibit beneficial properties mainly resulting from their high content in antioxidants, while several other phytochemical components (biopeptides, soluble fibers), which have been characterized, also contribute to the medicinal properties of Opuntia spp. that might have a great economic potential because these plants grow in arid and desert regions.
In the original research paper prepared by partners from Riga and from Zagreb, we found novel information about growth-modulating effects of the dihydropyridine derivatives (DHPs) with potential antioxidant capacities. Thus, I. Bruvere et al. revealed that cell-type-specific differences in the growth-modifying effects of the DHPs in vitro can be attributed only to the novel types of the DHPs, which differentiate these substances from their well-known predecessor diludine. Since the growth-modifying effects of the novel DHPs indicate possible differential effects on cancer and on nonmalignant cells, which might be also different from their antioxidant effects, these substances deserve particular attention and further studies.
The original research paper prepared by three teams from Karlsruhe, Germany, reveals the possible beneficial effects of pentaerythritol tetranitrate (PETN), which were not described before. Namely, pulmonary arterial hypertension was induced by the ranging dosage of the i.v. applied monocrotaline, which induced endothelial dysfunction, pulmonary vascular wall thickening, and fibrosis, as well as protein tyrosine nitration, thus causing an increase in pulmonary arterial pressure, followed by the increase in heart/body and lung/body weight ratios. However, in this study, S. Steven et al. found also that PETN therapy could act beneficially upon these pathophysiological processes, most likely by upregulation of heme oxygenase-1 (HO-1).
